08:24 AM EDT, 08/15/2024 (MT Newswires) -- CureVac ( CVAC ) reported a Q2 pre-tax loss Thursday of 71.2 million euros ($78.4 million), widening from a loss of 67.4 million euros a year earlier.

Revenue for the quarter ended June 30 was 14.4 million euros, up from 7.6 million euros a year earlier.

Analysts' estimates were not immediately available for comparison.

At the end of June, the company had 202.5 million euros in cash and cash equivalents. The company reaffirmed its expected cash runway into 2028.

The biotech company said that Chief Financial Officer Pierre Kemula will be departing at the end of his term on Oct. 31. CureVac ( CVAC ) has started a search for Kemula's successor.

Price: 3.3500, Change: +0.04, Percent Change: +1.21